At the recent ISIRV OptionsX conference in Singapore, the Gates foundation announced Grand Challenges Grantees for their Universal Influenza Vaccine Development call. This included The University of Cambridge (led by Jonathan Heeney) in partnership with the University of Regensburg, the University of Kent (Nigel Temperton), Imperial College London and Public Health England. This project is exciting for the Temperton lab as their influenza pseudotyping technologies are integral to the DIOS-UIVA (Digital Immune Optimized & Selected Universal Influenza Vaccine Antigens) pipeline. Both George Carnell and Rebecca Kinsley undertook their PhDs at the Viral Pseudotype Unit (Medway School of Pharmacy).
From left to right in photo: Rebecca Kinsley, George Carnell, Nigel Temperton and Jonathan Heeney.
